2022版美国儿科学会新生儿高胆红素血症管理指南解读

doi:10.7499/j.issn.1008-8830.2210119

摘要
图/表
参考文献(27)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (981 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要 2022年9月美国儿科学会更新了胎龄≥35周新生儿高胆红素血症管理指南，该指南在整理总结过去18年循证证据的基础上，对胎龄≥35周新生儿高胆红素血症的预防、风险评估、干预及随访等内容进行了更新，现就核心要点进行解读，旨在安全地降低胆红素脑病的风险及不必要的干预风险。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨静丽
	王建辉

关键词 ：高胆红素血症, 指南, 解读, 新生儿

Abstract：The American Academy of Pediatrics updated the guidelines for the management of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks in September 2022. Based on the evidence over the past 18 years, the guidelines are updated from the aspects of the prevention, risk assessment, intervention, and follow-up of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks. This article gives an interpretation of the key points in the guidelines, so as to safely reduce the risk of bilirubin encephalopathy and unnecessary intervention.

Key words： Hyperbilirubinemia Guideline Interpretation Newborn infant

收稿日期: 2022-10-26

基金资助:国家重点研发计划资助（2022YFC2704805）；重庆市科卫联合医学科研项目（2022MSXM137）。

通讯作者: 王建辉，男，副主任医师，副教授。Email：wangjh@cqmu.edu.cn。 E-mail: wangjh@cqmu.edu.cn

作者简介: 杨静丽，女，硕士，主治医师；

引用本文:

杨静丽,王建辉. 2022版美国儿科学会新生儿高胆红素血症管理指南解读[J]. 中国当代儿科杂志, 2023, 25(1): 11-17.

YANG Jing-Li,WANG Jian-Hui. Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants[J]. CJCP, 2023, 25(1): 11-17.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2210119 或 http://www.zgddek.com/CN/Y2023/V25/I1/11

	Olusanya BO, Teeple S, Kassebaum NJ. The contribution of neonatal jaundice to global child mortality: findings from the GBD 2016 study[J]. Pediatrics, 2018, 141(2): e20171471. PMID: 29305393. DOI: 10.1542/peds.2017-1471.
	Olusanya BO, Kaplan M, Hansen TWR. Neonatal hyperbilirubinaemia: a global perspective[J]. Lancet Child Adolesc Health, 2018, 2(8): 610-620. PMID: 30119720. DOI: 10.1016/S2352-4642(18)30139-1.
	American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2004, 114(1): 297-316. PMID: 15231951. DOI: 10.1542/peds.114.1.297.
	4 中华医学会儿科学分会新生儿学组, 《中华儿科杂志》编辑委员会. 新生儿高胆红素血症诊断和治疗专家共识[J]. 中华儿科杂志, 2014, 52(10): 745-748. DOI: 10.3760/cma.j.issn.0578-1310.2014.10.006.
	Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058859. PMID: 35927462. DOI: 10.1542/peds.2022-058859.
	Hynes S, Moore Z, Patton D, et al. Accuracy of transcutaneous bilirubin versus serum bilirubin measurement in preterm infants receiving phototherapy: a systematic review[J]. Adv Neonatal Care, 2020, 20(6): E118-E126. PMID: 32366804. DOI: 10.1097/ANC.0000000000000738.
	Yang ST, Liu FC, Chen HL. Comparison of transcutaneous and serum bilirubin before, under, and after phototherapy in term and late-preterm infants[J]. Kaohsiung J Med Sci, 2019, 35(11): 715-724. PMID: 31436020. DOI: 10.1002/kjm2.12121.
	Maisels MJ, Ostrea EM, Touch S, et al. Evaluation of a new transcutaneous bilirubinometer[J]. Pediatrics, 2004, 113(6): 1628-1635. PMID: 15173483. DOI: 10.1542/peds.113.6.1628.
	Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants[J]. Pediatrics, 2014, 134(2): e340-e345. PMID: 25049352. DOI: 10.1542/peds.2013-4299.
	Riskin A, Tamir A, Kugelman A, et al. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia?[J]. J Pediatr, 2008, 152(6): 782-787. PMID: 18492516. DOI: 10.1016/j.jpeds.2007.11.003.
	Setia S, Villaveces A, Dhillon P, et al. Neonatal jaundice in Asian, white, and mixed-race infants[J]. Arch Pediatr Adolesc Med, 2002, 156(3): 276-279. PMID: 11876673. DOI: 10.1001/archpedi.156.3.276.
	Kuzniewicz MW, Park J, Niki H, et al. Predicting the need for phototherapy after discharge[J]. Pediatrics, 2021, 147(5): e2020019778. PMID: 33903163. DOI: 10.1542/peds.2020-019778.
	Maisels MJ, Deridder JM, Kring EA, et al. Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia[J]. J Perinatol, 2009, 29(9): 612-617. PMID: 19421200. DOI: 10.1038/jp.2009.43.
	Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1): 154-168. PMID: 27429428. DOI: 10.1097/MPG.0000000000001334.
	Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements[J]. JAMA, 2020, 323(12): 1141-1150. PMID: 32207797. PMCID: PMC7093763. DOI: 10.1001/jama.2020.0837.
	Slaughter JL, Kemper AR, Newman TB. Technical report: diagnosis and management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058865. PMID: 35927519. DOI: 10.1542/peds.2022-058865.
	Wickremasinghe AC, Risley RJ, Kuzniewicz MW, et al. Risk of sensorineural hearing loss and bilirubin exchange transfusion thresholds[J]. Pediatrics, 2015, 136(3): 505-512. PMID: 26283777. DOI: 10.1542/peds.2014-3357.
	Wu YW, Kuzniewicz MW, Wickremasinghe AC, et al. Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study[J]. JAMA Pediatr, 2015, 169(3): 239-246. PMID: 25560920. DOI: 10.1001/jamapediatrics.2014.3036.
	Das RR, Naik SS. Neonatal hyperbilirubinemia and childhood allergic diseases: a systematic review[J]. Pediatr Allergy Immunol, 2015, 26(1): 2-11. PMID: 25229699. DOI: 10.1111/pai.12281.
	Newman TB, Wu YW, Kuzniewicz MW, et al. Childhood seizures after phototherapy[J]. Pediatrics, 2018, 142(4): e20180648. PMID: 30249623. DOI: 10.1542/peds.2018-0648.
	Bugaiski-Shaked A, Shany E, Mesner O, et al. Association between neonatal phototherapy exposure and childhood neoplasm[J]. J Pediatr, 2022, 245: 111-116. PMID: 35120988. DOI: 10.1016/j.jpeds.2022.01.046.
	Maisels MJ, Kring E. Rebound in serum bilirubin level following intensive phototherapy[J]. Arch Pediatr Adolesc Med, 2002, 156(7): 669-672. PMID: 12090833. DOI: 10.1001/archpedi.156.7.669.
	Lamola AA. A pharmacologic view of phototherapy[J]. Clin Perinatol, 2016, 43(2): 259-276. PMID: 27235206. DOI: 10.1016/j.clp.2016.01.004.
	Chang PW, Waite WM. Evaluation of home phototherapy for neonatal hyperbilirubinemia[J]. J Pediatr, 2020, 220: 80-85. PMID: 32067781. DOI: 10.1016/j.jpeds.2020.01.004.
	Chang PW, Newman TB. A simpler prediction rule for rebound hyperbilirubinemia[J]. Pediatrics, 2019, 144(1): e20183712. PMID: 31196939. DOI: 10.1542/peds.2018-3712.
	Wolf MF, Childers J, Gray KD, et al. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia[J]. J Perinatol, 2020, 40(10): 1506-1512. PMID: 32152492. PMCID: PMC8021453. DOI: 10.1038/s41372-020-0642-0.
	Watchko JF. Emergency release uncross-matched packed red blood cells for immediate double volume exchange transfusion in neonates with intermediate to advanced acute bilirubin encephalopathy: timely but insufficient?[J]. J Perinatol, 2018, 38(8): 947-953. PMID: 29997396. DOI: 10.1038/s41372-018-0168-x.